Colgate-Palmolive (CL) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 29, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Purchase Gregory Malcolm, Evp And Controller bought 7 shares at $71.79 ($503).
- Trade date
- Oct 4, 2022
- Disclosed to the SEC
- Nov 20, 2026
- Type
- Open-market purchase (code P)
Read the original SEC filing ↗All CL insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
CL insider transactions (Form 4)
Open-market purchases and sales. 85 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 20 NewSEC | Gregory MalcolmEvp And ControllerFirst buy | Buy | 78,542 held (+0%) | $71.79 | $503 | +37.9% | — |
| Nov 12SEC | Gregory MalcolmEvp And Controller | Sell | 4,10010,061 held (−29%) | $97.97 | $402K | +1.0% | — |
| Nov 9SEC | Lorrie M. NorringtonDirector | Sell | 4,17043,383 held (−9%) | $99.31 | $414K | -0.3% | — |
| Nov 6SEC | John HazlinChief Growth Officer | Sell | 23,37627,021 held (−46%) | $99.15 | $2.3M | -0.2% | — |
| Nov 6SEC | Noel R. WallaceCEO, President | Sell | 20,000359,700 held (−5%) | $100.26 | $2.0M | -1.3% | — |
| Nov 6SEC | Panagiotis TsourapasCOO | Sell | 19,9389,111 held (−69%) | $98.74 | $2.0M | +0.3% | — |
| Aug 26SEC | Panagiotis TsourapasCOO | Sell | 10,00064,901 held (−13%) | $92.05 | $920K | +7.5% | — |
| Aug 7SEC | John T. CahillDirector | Sell | 4,17028,373 held (−13%) | $93.37 | $389K | +6.0% | — |
| Aug 6SEC | Noel R. WallaceCEO, President | Sell | 161,021362,231 held (−31%) | $92.52 | $14.9M | +7.0% | — |
| Aug 6SEC | Noel R. WallaceCEO, President | Sell | 161,021362,231 held (−31%) | $91.92 | $14.8M | +7.7% | — |
| May 18SEC | Gregory MalcolmEvp And Controller | Sell | 2,30013,598 held (−14%) | $88.44 | $203K | +11.9% | — |
| May 11SEC | Sally MasseyChief People Officer | Sell | 8,59913,785 held (−38%) | $87.41 | $752K | +13.2% | — |
| Feb 13SEC | Panagiotis TsourapasCOO | Sell | 35,00010,415 held (−77%) | $94.61 | $3.3M | +4.6% | — |
| Feb 13SEC | Panagiotis TsourapasCOO | Sell | 15,00010,415 held (−59%) | $97.81 | $1.5M | +1.2% | — |
| Feb 12SEC | John HazlinChief Growth Officer | Sell | 20,98917,645 held (−54%) | $94.25 | $2.0M | +5.0% | — |
| Feb 10SEC | Gregory MalcolmEvp And Controller | Sell | 12,74711,879 held (−52%) | $94.91 | $1.2M | +4.3% | — |
| Feb 9SEC | Sally MasseyChief Human Resources Officer | Sell | 15,85113,751 held (−54%) | $95.03 | $1.5M | +4.2% | — |
| Feb 6SEC | Stanley J. Sutula IIICFO | Sell | 97,84355,310 held (−64%) | $94.27 | $9.2M | +5.0% | — |
| Feb 6SEC | Noel R. WallaceCEO, President | Sell | 45,568293,188 held (−13%) | $93.91 | $4.3M | +5.4% | — |
| Feb 6SEC | Jennifer DanielsGeneral Counsel | Sell | 22,00076,406 held (−22%) | $94.34 | $2.1M | +4.9% | — |
| Nov 24SEC | Sally MasseyChief Human Resources Officer | Sell | 1,23713,751 held (−8%) | $80.89 | $100K | +22.4% | — |
Similar past setups: not applicable. CL has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with CL in the Research Lab
CL has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Colgate-Palmolive insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $64.2M of CL stock on the open market; P/E 39.5 vs. a sector median of 21.2.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
CL insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $7.1M | 5 |
| Q3 2026 | — | 0 | $31.0M | 4 |
| Q2 2026 | — | 0 | $955K | 2 |
| Q1 2026 | — | 0 | $25.1M | 8 |
| Q4 2025 | — | 0 | $100K | 1 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Colgate-Palmolive insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $64.2M. 0 of 20 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
CL earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 30, 2026 | +1.0% | None | +4.6%S&P -2.2% | pending |
| Jul 31, 2026 | +0.7% | None | -1.9%S&P +2.2% | +0.2% |
| May 1, 2026 | +2.9% | None | +0.0%S&P -0.1% | -0.6% |
| Jan 30, 2026 | +1.4% | None | +7.8%S&P +0.2% | +3.7% |
| Oct 31, 2025 | -0.8% | None | -2.0%S&P +0.5% | +4.3% |
| Aug 1, 2025 | -3.8% | None | -0.6%S&P -0.1% | +0.5% |
| Apr 25, 2025 | +3.3% | None | -1.9%S&P +0.8% | +0.9% |
| Jan 31, 2025 | +4.0% | None | -4.2%S&P -1.2% | +5.4% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
CL short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Insiders at Colgate-Palmolive
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Noel R. WallaceCEO, President | — | $36.0M | Nov 6, 2026 | — | — |
| Stanley J. Sutula IIICFO | — | $9.2M | Sep 18, 2026 | — | — |
| Panagiotis TsourapasCOO | — | $7.7M | Nov 6, 2026 | — | — |
| John HazlinChief Growth Officer | — | $4.3M | Nov 6, 2026 | — | — |
| Sally MasseyChief People Officer | — | $2.4M | Sep 18, 2026 | — | — |
| Jennifer DanielsGeneral Counsel | — | $2.1M | Feb 25, 2026 | — | — |
| Gregory MalcolmEvp And Controller | $503 | $1.8M | Nov 20, 2026 | — | — |
| Lorrie M. NorringtonDirector | — | $414K | Nov 9, 2026 | 1 of 2 | — |
| John T. CahillDirector | — | $389K | Aug 7, 2026 | 2 of 3 | — |
| John P. BilbreyDirector | — | — | Oct 2, 2026 | — | — |
| Brian NewmanDirector | — | — | Oct 2, 2026 | — | — |
| Betsy FishboneGeneral Counsel | — | — | Sep 18, 2026 | — | — |
| Shane GrantCOO | — | — | Sep 18, 2026 | — | — |
| Christopher S. BoernerDirector | — | — | May 13, 2026 | 0 of 3 | — |
| Lisa EdwardsDirector | — | — | May 13, 2026 | — | — |
| C. Martin HarrisDirector | — | — | May 13, 2026 | — | — |
| Martina HundmejeanDirector | — | — | May 13, 2026 | — | — |
| Kimberly A. NelsonDirector | — | — | May 13, 2026 | — | — |
Board links: companies that share insiders with CL
Directors and executives who filed Form 4s for CL and another company in the last 12 months.
- ADSKAutodesk John T. Cahill Director here · Director at ADSK · latest filing Aug 7, 2026
- BMYBristol Myers Squibb Christopher S. Boerner Director here · CEO at BMY · latest filing Nov 3, 2026
- CASYCasey's Stanley J. Sutula III CFO here · Director at CASY · latest filing Sep 18, 2026
- CMICummins Kimberly A. Nelson Director here · Director at CMI · latest filing May 13, 2026
- CVSCVS Health Brian Newman Director here · CFO at CVS · latest filing Oct 2, 2026
- GEVGE Vernova Martina Hundmejean Director here · Director at GEV · latest filing May 18, 2026
- HUBSHubspot Lorrie M. Norrington Director here · Director at HUBS · latest filing Nov 9, 2026
- KHCKraft Heinz John T. Cahill Director here · Director at KHC · latest filing Aug 7, 2026
- LULULululemon Athletica Shane Grant COO here · Director at LULU · latest filing Sep 18, 2026
- STZConstellation Brands Jennifer Daniels General Counsel here · Director at STZ · latest filing Jul 14, 2026
Insider activity at other Consumer Staples companies
Same sector, ranked by insider buying in the last 90 days.
CL stock: common questions
Are Colgate-Palmolive insiders buying CL stock?
No. No Colgate-Palmolive insider reported an open-market purchase of CL in the past 12 months. The latest was Evp And Controller Gregory Malcolm bought $503 of CL at $71.79 — first open-market purchase in our records.
Are Colgate-Palmolive insiders selling CL stock?
9 insiders reported sales worth $64.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CL's P/E ratio?
CL trades at about 39.5 times trailing earnings, compared with a median of 21.2 for the Consumer Staples sector.
What is CL's 52-week range?
Over the past year CL has traded between $74.75 and $100.99. It last closed at $98.99 on Nov 20, 2026.